CytRx Corp. (Nasdaq: CYTR) reported positive interim results from a Phase 2 study of aldoxorubicin to treat brain cancer lifting the stock price 57 cents to $3.42.
CytRx reports positive interim results
January 06, 2015 at 13:32 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.